Nanette Barragán actually said...
I disagree with CMS's coverage decision to tightly restrict coverage for an entire class of FDA-approved Alzheimer's drugs.
Context
Barragan criticizes CMS for restricting coverage of approved Alzheimer's drugs.
03/28/2023